STAT+: Gilead’s Dan O’Day is pharma’s most charming executive — but with his deals falling apart, charm may not be enough
The news Gilead Sciences dropped Monday was so disappointing it irked even the nicest guy…
Category: STAT+
.jpg)
STAT+: AbbVie settles litigation with another drug maker over a biosimilar version of Humira
After months of squabbling over allegedly stolen trade secrets, AbbVie (ABBV) has settled litigation with…
STAT+: Congress moves toward giving FDA authority over synthetic nicotine products like Puff Bar
WASHINGTON — Lawmakers are within striking distance of closing the largest loophole in the Food…
STAT+: Congress considers a longer phase-out of looser, Covid-era telehealth policies
WASHINGTON — Lawmakers are considering extending the more flexible telehealth policies put in place during the…
STAT+: Mallinckrodt to pay $260 million to settle federal lawsuits over Medicaid rebates and kickbacks
After years of squabbling, Mallinckrodt agreed to pay $260 million to settle accusations that it…
STAT+: Pharmalittle: U.S. lawmaker proposes bill to curtail FDA’s accelerated approval; Moderna to enforce Covid patents in wealthy countries
Top of the morning to you. A shiny sun is enveloping the Pharmalot campus this…
STAT+: Moderna looks to enforce its Covid-19 vaccine patents in wealthy countries
Amid intense public pressure, Moderna (MRNA) updated a pledge not to enforce patents for its…
STAT+: A glaring gap in Congress’ surprise billing law leaves patients on the hook for pricey, out-of-network lab tests
For Soung Luy, it seemed easy: His primary care doctor told him he needed blood…
STAT+: FDA effort to improve clinical trial diversity failed to make a difference for Black patients, study finds
Six years ago, the U.S. Food and Drug Administration launched a five-year action plan to…
STAT+: Key Democrat moves to crack down on FDA accelerated approvals
WASHINGTON – A powerful Democratic lawmaker has introduced a bill that would dramatically rein in…
STAT+: Few public biotech companies disclose environmental, social, and governance steps
Environmental, social, and governance issues are gaining greater attention among investors, but only 30% of…
STAT+: Pharmalittle: White House bid for Covid drug funding hurt by transparency issue; Bluebird Bio runs short of cash
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: A key study of Gilead’s breast cancer drug meets goal, but withheld data raise doubts
Gilead Sciences said Monday that a large clinical trial of its drug Trodelvy achieved its…
STAT+: With cash running short, Bluebird Bio and its gene therapies face uncertain future
Bluebird Bio, the troubled developer of gene therapies, has warned that cash is running short,…
STAT+: Researchers question whether Amazon’s partnership with Teladoc will really improve access to health care
Amazon and Teladoc have pitched a new feature letting millions of consumers call doctors directly…
STAT+: Pharmalittle: Sacklers and states agree to $6 billion opioid settlement; Biogen layoffs get under way
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Microsoft closes $16B acquisition of Nuance, launching a bold experiment in health AI
AI’s next big health care experiment can now begin. Microsoft closed on a $16 billion…
STAT+: Washington state moves closer to creating the next prescription drug affordability board
In a closely watched development, House lawmakers in Washington state passed a bill to create…
STAT+: Even as it struggles, startup insurer Bright Health deepens its ties to Cigna
Bright Health is hemorrhaging money, raising questions not only about its future but also about…
STAT+: With Aduhelm in limbo, Biogen starts laying off employees
Biogen’s largest-ever corporate restructuring began Wednesday, as employees around the world got word they would…
STAT+: Pharmalittle: U.S. will share some coronavirus technologies with WHO; Civica Rx tries unconventional bid to make cheap insulin
Top of the morning to you, and a fine one it is. A shiny sun…
STAT+: Civica Rx has an ambitious plan to make low-cost insulin for all Americans. But can it work?
In an unconventional bid to widen access to insulin for Americans, a nonprofit announced plans…
.jpg)
STAT+: Why formally ending the pandemic is going to be a huge headache for the entire health care system
WASHINGTON — President Biden made it clear this week he wants to transition toward a…
STAT+: Awaiting ‘definitive’ Alzheimer’s drug data, Roche and Genentech launch ambitious new study
Partners Roche and Genentech are studying whether their investigational treatment for Alzheimer’s disease can prevent…
STAT+: Nevada joins a little-known, ambitious state consortium dedicated to better drug prices
After months of talks, the state of Nevada has joined a consortium formed by Oregon…
STAT+: Pharmalittle: U.S. Supreme Court examines when misprescribing is criminal; Biden calls for capping insulin at $35
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent
Takeover speculation has swirled around Aurinia Pharmaceuticals since late 2019 when its lead drug, Lupkyni,…
STAT+: Vesalius Therapeutics launches to develop treatments for common diseases
Flagship Pioneering, the Cambridge, Mass., life sciences investment firm that helped found Moderna over a…
STAT+: 3 burning questions spurred by the big CRISPR patent ruling
On Monday, the U.S. Patent and Trademark Office ruled that CRISPR patents key to developing…
STAT+: Supreme Court debates exactly when a doctors’ misprescribing becomes criminal
Supreme Court justices on Tuesday seemed divided over where to draw the line for what…
STAT+: Tennessee judge sanctions Endo for ‘coordinated strategy’ to withhold documents in opioid case
Endo International (ENDP) was sanctioned by a Tennessee state court judge for using a “coordinated…
STAT+: Pharmalittle: Broad Institute wins legal battle over CRISPR patents; Pfizer’s C. diff vaccine fails in study
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pfizer made Trump’s vaccine push harder than it needed to be, former Warp Speed official alleges in new book
WASHINGTON — Pfizer may have been the first company to deliver on the promises of…
STAT+: Strong evidence is becoming a business imperative for mental health tech startups
As smartphone apps that treat mental health conditions become more common, the companies making them…
STAT+: FDA approves second CAR-T cancer therapy to treat multiple myeloma, opening the door for greater access
The Food and Drug Administration on Monday approved a new CAR-T therapy for multiple myeloma, a…
STAT+: UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies
Ending the latest chapter in a years-long legal battle over who invented CRISPR, the U.S….
STAT+: Intellia Therapeutics shows improved, sustained effect from in vivo CRISPR treatment
Intellia Therapeutics said Monday that its CRISPR-based therapy for a genetic nerve disorder reduced the…
STAT+: Oregon withdraws a waiver request to run a closed Medicaid formulary
In response to a raft of concerns, Oregon has withdrawn a request made to federal…
STAT+: Ants, spiders, and mold: Why a big compounding pharmacy recently recalled all its products
Last December, a little known compounding pharmacy recalled all of its products due to “process…
STAT+: Pharmalittle: FTC’s top economist quits amid PBM-study spat; FDA clinical holds have become more common
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: STAT+: What biotech can learn from past stock market downturns
“Dumpster fire.” “Biotech bear market.” “A market rout.” Going by recent descriptions of the performance of…
STAT+: AI gone astray: How subtle shifts in patient data send popular algorithms reeling, undermining patient safety
A novel investigation by STAT and the Massachusetts Institute of Technology found that subtle shifts…
STAT+: Pharmalittle: J&J and wholesalers finalize opioid settlement; more than half of U.S. abortions involved a pill
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Johnson & Johnson, three pharma wholesalers finalize $26 billion opioid crisis settlement
Johnson & Johnson (JNJ) and three major pharmaceutical wholesalers have finalized nationwide settlements over their…
STAT+: NIH official accused of ‘bias’ against using a controversial law to address high drug prices
The campaign to use so-called march-in rights to widen access to a cancer drug is…
STAT+: With new trial data coming on Monday, Intellia CEO talks up the future of in vivo gene editing
In 1996, 32,655 Americans died from AIDS. A year later, that number was 16,685. The…
STAT+: Political pressure in the U.K. prompted more universities to report clinical trial results
Sometimes, sabre rattling works. Three years ago, a U.K. Parliamentary committee chair warned dozens of…
STAT+: Unraveling of Amicus spinout spells more trouble for gene therapy field
The abrupt dissolution of a blank-check merger on Thursday points to more trouble for the…
STAT+: Judge bars Shkreli from running another public company, fines him $1.4 million
A U.S. District Court judge has granted a request from the U.S. Securities and Exchange…
STAT+: Pharmalittle: Drugmakers push back against Medicare on Alzheimer’s drug; South Africa says Merck Covid pill isn’t cost-effective
Good morning, everyone, and how are you today? Gray skies are hovering over the Pharmalot…